Experimental combo for Graft-Versus-Host disease fails to enroll

NCT ID NCT01453140

Terminated Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a mix of drugs (cyclophosphamide, sirolimus, low-dose IL-2, and azacitidine) to treat severe graft-versus-host disease that didn't respond to steroids. Only 3 patients were enrolled before the trial was stopped early. The goal was to see if the treatment could control the immune reaction after a stem cell transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide, sirolimus, low-dose IL-2, and azacitidine
What this could lead to: If successful, this approach could offer a new way to control severe graft-versus-host disease when steroids fail.
What could go wrong: The trial was terminated early with only 3 participants, so results are very limited. The combination of drugs carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.